Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Influenza

  Free Subscription


Articles published in Antiviral Res

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    June 2022
  1. JONES JC, Rovito SW, Penaflor MK, Webby RJ, et al
    Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
    Antiviral Res. 2022 Jun 20:105369. doi: 10.1016/j.antiviral.2022.105369.
    PubMed     Abstract available


    May 2022
  2. PRASHAR P, Swain S, Adhikari N, Aryan P, et al
    A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies.
    Antiviral Res. 2022 May 28:105349. doi: 10.1016/j.antiviral.2022.105349.
    PubMed     Abstract available


  3. LIN Q, Lu C, Hong Y, Li R, et al
    Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
    Antiviral Res. 2022 May 20:105345. doi: 10.1016/j.antiviral.2022.105345.
    PubMed     Abstract available


  4. ROY A, Alhammad YM, McDonald P, Johnson DK, et al
    Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
    Antiviral Res. 2022 May 19:105344. doi: 10.1016/j.antiviral.2022.105344.
    PubMed     Abstract available


  5. WEIL T, Lawrenz J, Seidel A, Munch J, et al
    Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor.
    Antiviral Res. 2022 May 19:105343. doi: 10.1016/j.antiviral.2022.105343.
    PubMed     Abstract available


  6. VANHULLE E, Stroobants J, Provinciael B, Camps A, et al
    SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening.
    Antiviral Res. 2022 May 17:105342. doi: 10.1016/j.antiviral.2022.105342.
    PubMed     Abstract available


  7. FINDLAY-WILSON S, Easterbrook L, Smith S, Pope N, et al
    Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
    Antiviral Res. 2022 May 6:105332. doi: 10.1016/j.antiviral.2022.105332.
    PubMed     Abstract available


  8. PITTS J, Babusis D, Vermillion MS, Subramanian R, et al
    Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection.
    Antiviral Res. 2022 May 4:105329. doi: 10.1016/j.antiviral.2022.105329.
    PubMed     Abstract available


  9. ZHAO L, Yan Y, Dai Q, Wang Z, et al
    The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection.
    Antiviral Res. 2022;201:105296.
    PubMed     Abstract available


    April 2022
  10. FOO CS, Abdelnabi R, Kaptein SJF, Zhang X, et al
    HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Antiviral Res. 2022;202:105311.
    PubMed     Abstract available


  11. VANMECHELEN B, Stroobants J, Chiu W, Schepers J, et al
    Identification of novel Ebola virus inhibitors using biologically contained virus.
    Antiviral Res. 2022;200:105294.
    PubMed     Abstract available


    March 2022
  12. WAGATSUMA K, Saito R, Chon I, Phyu WW, et al
    Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Antiviral Res. 2022;201:105310.
    PubMed     Abstract available


  13. HUANG J, Liu X, Sun Y, Huang C, et al
    Porcine beta-defensin 2 confers enhanced resistance to swine flu infection in transgenic pigs and alleviates swine influenza virus-induced apoptosis possibly through interacting with host SLC25A4.
    Antiviral Res. 2022;201:105292.
    PubMed     Abstract available


  14. UENO M, Iwata-Yoshikawa N, Matsunaga A, Okamura T, et al
    Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
    Antiviral Res. 2022;201:105297.
    PubMed     Abstract available


  15. BROWN SK, Tseng YY, Aziz A, Baz M, et al
    Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
    Antiviral Res. 2022;200:105280.
    PubMed     Abstract available


  16. LAI GC, Chao TL, Lin SY, Kao HC, et al
    Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.
    Antiviral Res. 2022;200:105290.
    PubMed     Abstract available


  17. GOVORKOVA EA, Takashita E, Daniels RS, Fujisaki S, et al
    Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.
    Antiviral Res. 2022 Mar 12:105281. doi: 10.1016/j.antiviral.2022.105281.
    PubMed     Abstract available


  18. PASQUERO S, Gugliesi F, Griffante G, Dell'Oste V, et al
    Novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2.
    Antiviral Res. 2022;200:105278.
    PubMed     Abstract available


  19. SCHOLLE MD, O'Kane PT, Dib S, Gurard-Levin ZA, et al
    Label-free duplex SAMDI-MS screen reveals novel SARS-CoV-2 3CLpro inhibitors.
    Antiviral Res. 2022;200:105279.
    PubMed     Abstract available


  20. CHEN KY, Krischuns T, Varga LO, Harigua-Souiai E, et al
    A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Antiviral Res. 2022 Mar 9:105272. doi: 10.1016/j.antiviral.2022.105272.
    PubMed     Abstract available


  21. TANAKA T, Saito A, Suzuki T, Miyamoto Y, et al
    Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening.
    Antiviral Res. 2022;199:105268.
    PubMed     Abstract available


    February 2022
  22. TSAI TI, Khalili JS, Gilchrist M, Waight AB, et al
    ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern.
    Antiviral Res. 2022 Feb 28:105271. doi: 10.1016/j.antiviral.2022.105271.
    PubMed     Abstract available


  23. SACHSE M, Tenorio R, Fernandez de Castro I, Munoz-Basagoiti J, et al
    Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis.
    Antiviral Res. 2022 Feb 26:105270. doi: 10.1016/j.antiviral.2022.105270.
    PubMed     Abstract available


    January 2022
  24. ZHAO J, Liu Q, Yi D, Li Q, et al
    5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.
    Antiviral Res. 2022 Jan 28:105254. doi: 10.1016/j.antiviral.2022.105254.
    PubMed     Abstract available


  25. VANGEEL L, Chiu W, De Jonghe S, Maes P, et al
    Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Antiviral Res. 2022 Jan 24:105252. doi: 10.1016/j.antiviral.2022.105252.
    PubMed     Abstract available


  26. ABDELNABI R, Foo CS, Zhang X, Lemmens V, et al
    The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.
    Antiviral Res. 2022 Jan 20:105253. doi: 10.1016/j.antiviral.2022.105253.
    PubMed     Abstract available


  27. FOCOSI D, Maggi F, McConnell S, Casadevall A, et al
    Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis.
    Antiviral Res. 2022;198:105247.
    PubMed     Abstract available


  28. WILLIAMSON BN, Perez-Perez L, Schwarz B, Feldmann F, et al
    Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2.
    Antiviral Res. 2022 Jan 12:105246. doi: 10.1016/j.antiviral.2022.105246.
    PubMed     Abstract available


    December 2021
  29. MCKIMM-BRESCHKIN JL, Hay AJ, Cao B, Cox RJ, et al
    COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference.
    Antiviral Res. 2021 Dec 18:105227. doi: 10.1016/j.antiviral.2021.105227.
    PubMed     Abstract available


  30. BHATNAGAR N, Kim KH, Subbiah J, Park BR, et al
    Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
    Antiviral Res. 2021 Dec 18:105229. doi: 10.1016/j.antiviral.2021.105229.
    PubMed     Abstract available


    November 2021
  31. COCHIN M, Touret F, Driouich JS, Moureau G, et al
    Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
    Antiviral Res. 2021;197:105212.
    PubMed     Abstract available


  32. ZHAO J, Zhang G, Zhang Y, Yi D, et al
    2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Antiviral Res. 2021;196:105209.
    PubMed     Abstract available


  33. VANDERLINDEN E, Marchand A, Van Berwaer R, van Dam W, et al
    A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin.
    Antiviral Res. 2021 Nov 15:105208. doi: 10.1016/j.antiviral.2021.105208.
    PubMed     Abstract available


  34. SVILENOV HL, Sacherl J, Reiter A, Wolff LS, et al
    Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
    Antiviral Res. 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
    PubMed     Abstract available


  35. QIU H, Yuan XY, Cabral T, Manguiat K, et al
    Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
    Antiviral Res. 2021 Nov 8:105206. doi: 10.1016/j.antiviral.2021.105206.
    PubMed     Abstract available


    August 2021
  36. GARCIA-DORIVAL I, Cuesta-Geijo MA, Barrado-Gil L, Galindo I, et al
    Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
    Antiviral Res. 2021 Aug 24:105167. doi: 10.1016/j.antiviral.2021.105167.
    PubMed     Abstract available


  37. ESCAFFRE O, Freiberg AN
    Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
    Antiviral Res. 2021 Aug 9:105162. doi: 10.1016/j.antiviral.2021.105162.
    PubMed     Abstract available


  38. LEACH A, Ilca FT, Akbar Z, Ferrari M, et al
    A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Antiviral Res. 2021 Aug 7:105147. doi: 10.1016/j.antiviral.2021.105147.
    PubMed     Abstract available


  39. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
    Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
    Antiviral Res. 2021;194:105158.
    PubMed     Abstract available


    July 2021
  40. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
    Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
    Antiviral Res. 2021;193:105142.
    PubMed     Abstract available


  41. TOURET F, Driouich JS, Cochin M, Petit PR, et al
    Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
    Antiviral Res. 2021;193:105137.
    PubMed     Abstract available


  42. GAN ES, Syenina A, Linster M, Ng B, et al
    A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
    Antiviral Res. 2021;193:105138.
    PubMed     Abstract available


  43. PARK JH, Kim B, Antigua KJC, Jeong JH, et al
    Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model.
    Antiviral Res. 2021;193:105126.
    PubMed     Abstract available


  44. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
    Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
    Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
    PubMed     Abstract available


    June 2021
  45. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
    A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
    Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
    PubMed     Abstract available


  46. KASHYAP T, Murray J, Walker CJ, Chang H, et al
    Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
    Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
    PubMed     Abstract available


    May 2021
  47. CHONG Y, Kawai N, Tani N, Bando T, et al
    Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Antiviral Res. 2021;192:105092.
    PubMed     Abstract available


    April 2021
  48. SVYATCHENKO SV, Goncharova NI, Marchenko VY, Kolosova NP, et al
    An influenza A(H5N8) virus isolated during an outbreak at a poultry farm in Russia in 2017 has an N294S substitution in the neuraminidase and shows reduced susceptibility to oseltamivir.
    Antiviral Res. 2021 Apr 29:105079. doi: 10.1016/j.antiviral.2021.105079.
    PubMed     Abstract available


  49. ZHAO J, Guo S, Yi D, Li Q, et al
    A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Antiviral Res. 2021;190:105078.
    PubMed     Abstract available


  50. DU R, Cooper L, Chen Z, Lee H, et al
    Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
    Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
    PubMed     Abstract available


    March 2021
  51. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
    Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
    Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
    PubMed     Abstract available


  52. ROOSENHOFF R, Schutten M, Reed V, Clinch B, et al
    Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
    Antiviral Res. 2021 Mar 10:105060. doi: 10.1016/j.antiviral.2021.105060.
    PubMed     Abstract available


  53. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
    Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
    Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
    PubMed     Abstract available


    February 2021
  54. PATEL MC, Chesnokov A, Jones J, Mishin VP, et al
    Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.
    Antiviral Res. 2021;188:105035.
    PubMed     Abstract available


  55. HIDEKAZU OSADA, Chon I, Phyu WW, Wagatsuma K, et al
    Development of cycling probe based real-time PCR methodology for influenza A viruses possessing the PA/I38T amino acid substitution associated with reduced baloxavir susceptibility.
    Antiviral Res. 2021 Feb 9:105036. doi: 10.1016/j.antiviral.2021.105036.
    PubMed     Abstract available


  56. MARTIN R, Li J, Parvangada A, Perry J, et al
    Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
    Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
    PubMed     Abstract available


    January 2021
  57. LIU C, Boland S, Scholle MD, Bardiot D, et al
    Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
    Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
    PubMed     Abstract available


  58. ZHU Q, Zhang Y, Wang L, Yao X, et al
    Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
    PubMed     Abstract available


  59. DU R, Cheng H, Cui Q, Peet NP, et al
    Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins.
    Antiviral Res. 2021;186:105013.
    PubMed     Abstract available


    November 2020
  60. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
    Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
    Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
    PubMed     Abstract available


  61. ZHANG Y, Song W, Chen S, Yuan Z, et al
    A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
    Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
    PubMed     Abstract available


  62. HEJDANEK J, Radilova K, Pachl P, Hodek J, et al
    Structural characterization of the interaction between the C-terminal domain of the influenza polymerase PA subunit and an optimized small peptide inhibitor.
    Antiviral Res. 2020 Nov 6:104971. doi: 10.1016/j.antiviral.2020.104971.
    PubMed     Abstract available


  63. ZARAKET H, Hurt AC, Clinch B, Barr I, et al
    Burden of influenza B virus infection and considerations for clinical management.
    Antiviral Res. 2020 Nov 4:104970. doi: 10.1016/j.antiviral.2020.104970.
    PubMed     Abstract available


    October 2020
  64. CHOI SW, Shin JS, Park SJ, Jung E, et al
    Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
    PubMed     Abstract available


    September 2020
  65. SAITO R, Osada H, Wagatsuma K, Chon I, et al
    Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Antiviral Res. 2020;183:104951.
    PubMed     Abstract available


  66. ZHU Q, Hu H, Liu H, Shen H, et al
    A synthetic STING agonist inhibits the replication of Human Parainfluenza Virus 3 and Rhinovirus 16 through distinct mechanisms.
    Antiviral Res. 2020 Sep 16:104933. doi: 10.1016/j.antiviral.2020.104933.
    PubMed     Abstract available


  67. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
    Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
    PubMed     Abstract available


  68. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
    Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
    PubMed     Abstract available


    August 2020
  69. PATEL MC, Mishin VP, De La Cruz JA, Chesnokov A, et al
    Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.
    Antiviral Res. 2020 Aug 13:104906. doi: 10.1016/j.antiviral.2020.104906.
    PubMed     Abstract available


  70. LI W, Li J, Sun M, Yang L, et al
    Viperin protein inhibits the replication of caprine parainfluenza virus 3 (CPIV 3) by interaction with viral N protein.
    Antiviral Res. 2020 Aug 12:104903. doi: 10.1016/j.antiviral.2020.104903.
    PubMed     Abstract available


  71. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
    Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
    Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
    PubMed     Abstract available


  72. MOHR PG, Williams J, Tashiro M, Streltsov VA, et al
    Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.
    Antiviral Res. 2020 Aug 1:104895. doi: 10.1016/j.antiviral.2020.104895.
    PubMed     Abstract available


  73. BIALY D, Shelton H
    Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.
    Antiviral Res. 2020 Aug 1:104886. doi: 10.1016/j.antiviral.2020.104886.
    PubMed     Abstract available


    July 2020
  74. OKAMOTO M, Toyama M, Baba M
    The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
    PubMed     Abstract available


  75. CONZELMANN C, Gilg A, Gross R, Schutz D, et al
    An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
    Antiviral Res. 2020 Jul 29:104882. doi: 10.1016/j.antiviral.2020.104882.
    PubMed     Abstract available


  76. CAI W, Wen H, Zhou Q, Wu L, et al
    14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activity.
    Antiviral Res. 2020 Jul 20:104885. doi: 10.1016/j.antiviral.2020.104885.
    PubMed     Abstract available


  77. GALLIAN P, Pastorino B, Morel P, Chiaroni J, et al
    Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
    Antiviral Res. 2020 Jul 14:104880. doi: 10.1016/j.antiviral.2020.104880.
    PubMed     Abstract available


  78. PIZZORNO A, Padey B, Dubois J, Julien T, et al
    In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Antiviral Res. 2020 Jul 14:104878. doi: 10.1016/j.antiviral.2020.104878.
    PubMed     Abstract available


  79. VENISSE N, Peytavin G, Bouchet S, Gagnieu MC, et al
    Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
    Antiviral Res. 2020 Jul 10:104866. doi: 10.1016/j.antiviral.2020.104866.
    PubMed     Abstract available


  80. PAN X, Zhou P, Fan T, Wu Y, et al
    Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
    PubMed     Abstract available


  81. KIM SY, Jin W, Sood A, Montgomery DW, et al
    Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
    Antiviral Res. 2020 Jul 9:104873. doi: 10.1016/j.antiviral.2020.104873.
    PubMed     Abstract available


  82. SALINAS FM, Nebreda AD, Vazquez L, Gentilini MV, et al
    Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
    Antiviral Res. 2020;179:104817.
    PubMed     Abstract available


    June 2020
  83. MATYUSHENKO V, Kotomina T, Kudryavtsev I, Mezhenskaya D, et al
    Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell respo
    Antiviral Res. 2020 Jun 22:104864. doi: 10.1016/j.antiviral.2020.104864.
    PubMed     Abstract available


  84. TAKASHITA E, Abe T, Morita H, Nagata S, et al
    Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment.
    Antiviral Res. 2020 Jun 20:104828. doi: 10.1016/j.antiviral.2020.104828.
    PubMed     Abstract available


  85. JOCKUSCH S, Tao C, Li X, Anderson TK, et al
    A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
    Antiviral Res. 2020;180:104857.
    PubMed     Abstract available


  86. TILMANIS D, Koszalka P, Barr IG, Rossignol JF, et al
    Host-targeted Nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
    Antiviral Res. 2020 Jun 13:104851. doi: 10.1016/j.antiviral.2020.104851.
    PubMed     Abstract available


  87. SHANNON A, Le NT, Selisko B, Eydoux C, et al
    Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Antiviral Res. 2020;178:104793.
    PubMed     Abstract available


    May 2020
  88. TAI W, Zhang X, He Y, Jiang S, et al
    Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Antiviral Res. 2020 May 13:104820. doi: 10.1016/j.antiviral.2020.104820.
    PubMed     Abstract available


  89. BLOCKUS S, Sake SM, Wetzke M, Grethe C, et al
    Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
    Antiviral Res. 2020;177:104774.
    PubMed     Abstract available


    April 2020
  90. MANTLO E, Bukreyeva N, Maruyama J, Paessler S, et al
    Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Antiviral Res. 2020;179:104811.
    PubMed     Abstract available


  91. ABED Y, Fage C, Checkmahomed L, Venable MC, et al
    Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
    Antiviral Res. 2020 Apr 25:104807. doi: 10.1016/j.antiviral.2020.104807.
    PubMed     Abstract available


  92. BRAY M, Rayner C, Noel F, Jans D, et al
    Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
    Antiviral Res. 2020 Apr 21:104805. doi: 10.1016/j.antiviral.2020.104805.
    PubMed    


  93. LAURE M, Hamza H, Koch-Heier J, Quernheim M, et al
    Antiviral efficacy against Influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model.
    Antiviral Res. 2020 Apr 15:104806. doi: 10.1016/j.antiviral.2020.104806.
    PubMed     Abstract available


  94. SALLARD E, Lescure FX, Yazdanpanah Y, Mentre F, et al
    Type 1 interferons as a potential treatment against COVID-19.
    Antiviral Res. 2020;178:104791.
    PubMed     Abstract available


  95. SUZUKI S, Shichinohe S, Itoh Y, Nakayama M, et al
    Low replicative fitness of neuraminidase inhibitor-resistant H7N9 avian influenza A virus with R292K substitution in neuraminidase in cynomolgus macaques compared with I222T substitution.
    Antiviral Res. 2020 Apr 6:104790. doi: 10.1016/j.antiviral.2020.104790.
    PubMed     Abstract available


  96. TANG T, Bidon M, Jaimes JA, Whittaker GR, et al
    Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
    Antiviral Res. 2020 Apr 6:104792. doi: 10.1016/j.antiviral.2020.104792.
    PubMed     Abstract available


  97. CALY L, Druce JD, Catton MG, Jans DA, et al
    The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Apr 3:104787. doi: 10.1016/j.antiviral.2020.104787.
    PubMed     Abstract available


  98. CHOY KT, Yin-Lam Wong A, Kaewpreedee P, Sia SF, et al
    Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Antiviral Res. 2020 Apr 3:104786. doi: 10.1016/j.antiviral.2020.104786.
    PubMed     Abstract available


    March 2020
  99. SOLDEVILA N, Toledo D, Ortiz de Lejarazu R, Tamames S, et al
    Effect of antiviral treatment in older patients hospitalized with confirmed influenza.
    Antiviral Res. 2020 Mar 29:104785. doi: 10.1016/j.antiviral.2020.104785.
    PubMed     Abstract available


  100. JALILY PH, Duncan MC, Fedida D, Wang J, et al
    Put a cork in it: Plugging the M2 viral ion channel to sink influenza.
    Antiviral Res. 2020 Mar 27:104780. doi: 10.1016/j.antiviral.2020.104780.
    PubMed     Abstract available


  101. HUSSEIN AFA, Cheng H, Tundup S, Antanasijevic A, et al
    Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus.
    Antiviral Res. 2020 Mar 25:104782. doi: 10.1016/j.antiviral.2020.104782.
    PubMed     Abstract available


  102. SLOAN SE, Szretter KJ, Sundaresh B, Narayan KM, et al
    Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Antiviral Res. 2020 Mar 6:104763. doi: 10.1016/j.antiviral.2020.104763.
    PubMed     Abstract available


  103. TOURET F, de Lamballerie X
    Of chloroquine and COVID-19.
    Antiviral Res. 2020;177:104762.
    PubMed     Abstract available


  104. SIGRIST C, Bridge A, Le Mercier P
    A potential role for integrins in host cell entry by SARS-CoV-2.
    Antiviral Res. 2020 Mar 1:104759. doi: 10.1016/j.antiviral.2020.104759.
    PubMed    


    February 2020
  105. QIU H, Andersen H, Tarbet EB, Muhammad FS, et al
    Efficacy of anti-influenza immunoglobulin (FLU-IGIV) in ferrets and mice infected with 2009 pandemic influenza virus.
    Antiviral Res. 2020 Feb 27:104753. doi: 10.1016/j.antiviral.2020.104753.
    PubMed     Abstract available


  106. KUMARI R, Guo Z, Kumar A, Wiens M, et al
    Influenza virus NS1- C/EBPbeta gene regulatory complex inhibits RIG-I transcription.
    Antiviral Res. 2020 Feb 21:104747. doi: 10.1016/j.antiviral.2020.104747.
    PubMed     Abstract available


  107. MIFSUD EJ, Tilmanis D, Oh DY, Ming-Kay Tai C, et al
    Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
    Antiviral Res. 2020 Feb 20:104751. doi: 10.1016/j.antiviral.2020.104751.
    PubMed     Abstract available


    January 2020
  108. TAKASHITA E, Daniels RS, Fujisaki S, Gregory V, et al
    Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
    Antiviral Res. 2020 Jan 28:104718. doi: 10.1016/j.antiviral.2020.104718.
    PubMed     Abstract available


    November 2019
  109. PASCUA PNQ, Marathe BM, Bisen S, Webby RJ, et al
    Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions.
    Antiviral Res. 2019 Nov 29:104669. doi: 10.1016/j.antiviral.2019.104669.
    PubMed     Abstract available


    February 2019
  110. SCHOGLER A, Caliaro O, Brugger M, Oliveira Esteves BI, et al
    Modulation of the unfolded protein response pathway as an antiviral approach in airway epithelial cells.
    Antiviral Res. 2019;162:44-50.
    PubMed     Abstract available


    January 2019
  111. ZHANG K, Li C, Luo YS, Wen L, et al
    Establishment of a lethal aged mouse model of human respiratory syncytial virus infection.
    Antiviral Res. 2019;161:125-133.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: